Torrent Pharmaceuticals on Wednesday said it has entered a non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan in India. Vonoprozan is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of acid related disorders gastroesophageal reflux disease.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/efJ1RhC
via IFTTT
No comments:
Post a Comment